MFIM
ABEO icon

Mesirow Financial Investment Management’s Abeona Therapeutics ABEO Stock Holding History

Mesirow Financial Investment Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-807
Closed -$258K – 59
2018
Q3 		$258K Sell
807
-64
-7% -$22.7K 1.33% 46
2018
Q2 		$348K Buy
+871
New +$381K 1.55% 36

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Mesirow Financial Investment Management's ABEO Position: Q4 2018 in Review

Mesirow Financial Investment Management sold out of Abeona Therapeutics (ABEO) in Q4 2018, closing a stake of 807 shares — an estimated $258K sold.

Mesirow Financial Investment Management first reported a position in ABEO in Q2 2018 and held it in 2 quarters. The position peaked at $348K in Q2 2018. 99 funds tracked by Wall St. Rank hold ABEO as of Q4 2018.

  • Mesirow Financial Investment Management reported no remaining Abeona Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Mesirow Financial Investment Management sold 807 Abeona Therapeutics shares in Q4 2018, an estimated $258K.
  • Mesirow Financial Investment Management first reported a position in Abeona Therapeutics in Q2 2018 and held it in 2 quarters.
  • Mesirow Financial Investment Management's Abeona Therapeutics position peaked at $348K in Q2 2018.
  • 99 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2018.

Based on Mesirow Financial Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.